// App-Quantinova.ai

e15500 : Neoadjuvant PD-1 blockade combined with chemotherapy followed by concurrent immunoradiotherapy for locally advanced anal canal squamous carcinoma patients: Antitumor efficacy, safety and biomarker.

Researchers

Presenter

  • Weiwei Xiao

Principal Investigators

  • Yan Yuan

  • SuiHai Wang

  • Peiqiang Cai

  • BaoQing Chen

  • Rong Zhang

  • ZhiFan Zeng

  • Yuanhong Gao

Medical Centers

  • Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China

  • Collaborative Innovation Center for Cancer Medicine, Guangzhou, China

  • Sun Yat-Sen University Cancer Center, Guangdzhou, Guangdong, China

  • Southern Medical University, Guangzhou, China

  • Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China

  • GuangZhou, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Programmed cell death protein 1

Drug/Treatment

  • JS001

  • Docetaxel

  • Cisplatin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved